CoChat

Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria

Chu, Cindy S, Phyo, Aung Pyae, Lwin, Khin Maung, Win, Htun Htun, San, Thida, Aung, Aye Aye, Raksapraidee, Rattanaporn, Carrara, Verena I, Bancone, Germana, Watson, James, Moore, Kerryn A, Wiladphaingern, Jacher, Proux, Stéphane, Sriprawat, Kanlaya, Winterberg, Markus, Cheah, Phaik Yeong, Chue, Amy L, Tarning, Joel, Imwong, Mallika, Nosten, François, White, Nicholas J · 2018 · Clinical Infectious Diseases
Cited by 64

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Vivax malaria relapses frequently even in low-transmission settings. Chloroquine delays but does not prevent recurrences. Adding primaquine to a slowly eliminated schizonticide significantly reduces recurrences and improves hematocrit, but this advantage is offset by hemolysis in G6PD-deficient females.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cid/ciy319

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 22

  1. Whorton, 1947, The Chesson strain of Plasmodium vivax malaria; factors influencing the incubation period, J Infect Dis, 80, 223, 10.1093/infdis/80.3.223 · doi:10.1093/infdis/80.3.223
  2. White, 2011, Determinants of relapse periodicity in Plasmodium vivax malaria, Malar J, 10, 297, 10.1186/1475-2875-10-297 · DOI · Paper page
  3. Commons, 2017, The vivax surveyor: online mapping database for Plasmodium vivax clinical trials, Int J Parasitol Drugs Drug Resist, 7, 181, 10.1016/j.ijpddr.2017.03.003 · DOI
  4. Pukrittayakamee, 2000, Therapeutic responses to different antimalarial drugs in vivax malaria, Antimicrob Agents Chemother, 44, 1680, 10.1128/AAC.44.6.1680-1685.2000 · DOI · Paper page
  5. Baird, 1997, Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels, Am J Trop Med Hyg, 56, 621, 10.4269/ajtmh.1997.56.621 · DOI · Paper page
  6. Russell, 2003, Simple in vitro assay for determining the sensitivity of Plasmodium vivax isolates from fresh human blood to antimalarials in areas where P. vivax is endemic, Antimicrob Agents Chemother, 47, 170, 10.1128/AAC.47.1.170-173.2003 · DOI
  7. Nuchprayoon, 2008, Glucose-6-phosphate dehydrogenase mutations in Mon and Burmese of southern Myanmar, J Hum Genet, 53, 48, 10.1007/s10038-007-0217-3 · DOI
  8. Price, 2001, Factors contributing to anemia after uncomplicated falciparum malaria, Am J Trop Med Hyg, 65, 614, 10.4269/ajtmh.2001.65.614 · DOI · Paper page
  9. Sagara, 2014, Modelling recurrent events: comparison of statistical models with continuous and discontinuous risk intervals on recurrent malaria episodes data, Malar J, 13, 293, 10.1186/1475-2875-13-293 · DOI
  10. Luxemburger, 1999, Treatment of vivax malaria on the western border of Thailand, Trans R Soc Trop Med Hyg, 93, 433, 10.1016/S0035-9203(99)90149-9 · DOI
  11. Phyo, 2011, Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial, Clin Infect Dis, 53, 977, 10.1093/cid/cir631 · DOI · Paper page
  12. Most, 1963, Clinical trials of anti-malarial drugs, 525
  13. Sutanto, 2013, Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia, Antimicrob Agents Chemother, 57, 1128, 10.1128/AAC.01879-12 · DOI
  14. Nelwan, 2015, Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia, BMC Med, 13, 294, 10.1186/s12916-015-0535-9 · DOI
  15. Betuela, 2012, Relapses contribute significantly to the risk of Plasmodium vivax infection and disease in Papua New Guinean children 1–5 years of age, J Infect Dis, 206, 1771, 10.1093/infdis/jis580 · DOI · Paper page
  16. Pukrittayakamee, 1994, Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria, J Infect Dis, 169, 932, 10.1093/infdis/169.4.932 · DOI
  17. Pybus, 2013, The metabolism of primaquine to its active metabolite is dependent on CYP 2D6, Malar J, 12, 212, 10.1186/1475-2875-12-212 · DOI · Paper page
  18. St Jean, 2016, Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the phase 2b DETECTIVE trial, Malar J, 15, 97, 10.1186/s12936-016-1145-5 · DOI
  19. Bickerton-Blackburn, 1948, Observations on the development of resistance to vivax malaria, Trans R Soc Trop Med Hyg, 42, 117, 10.1016/0035-9203(48)90020-0 · doi:10.1016/0035-9203(48)90020-0
  20. Chu, 2017, Haemolysis in G6PD heterozygous females treated with primaquine for Plasmodium vivax malaria: a nested cohort in a trial of radical curative regimens, PLoS Med, 14, e1002224, 10.1371/journal.pmed.1002224 · DOI · Paper page
  21. Tjitra, 2008, Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia, PLoS Med, 5, e128, 10.1371/journal.pmed.0050128 · DOI · Paper page
  22. Genton, 2008, Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea, PLoS Med, 5, e127, 10.1371/journal.pmed.0050127 · DOI · Paper page

Cited by

See all 64

Metadata

Authors
Chu, C. S., Phyo, A. P., Lwin, K. M., Win, H. H., San, T., Aung, A. A., Raksapraidee, R., Carrara, V. I., Bancone, G., Watson, J., Moore, K. A., Wiladphaingern, J., Proux, S., Sriprawat, K., Winterberg, M., Cheah, P. Y., Chue, A. L., Tarning, J., Imwong, M., Nosten, F., & White, N. J.
Venue
Clinical Infectious Diseases
Published
2018-06-08
Volume
67
Issue
10
Pages
1543-1549
ISSN
  • 1058-4838
  • 1537-6591
Cited by
64
References
3
Language
en
Funders
Wellcome Trust (089179/Z/09/Z)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.